EW Stock Recent News

Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday.

Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Larry Wood - Corporate VP and Group President of TAVR & Surgical Structural Heart Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Christopher Pasquale - Nephron Research LLC Operator Greetings, and welcome to the Edwards Lifesciences Second

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Edwards Lifesciences raised its 2025 sales forecast on Thursday, citing strong demand for its artificial heart valves and other medical devices, after posting better-than-expected results for the second quarter.

Edwards Lifesciences stock jumped late Thursday after the medtech company beat second-quarter forecasts and hiked its outlook.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomati.

EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.

Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.